Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1391&sort=-program_reference_codes
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_reference_codes", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-program_reference_codes", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-program_reference_codes", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1390&sort=-program_reference_codes" }, "data": [ { "type": "Grant", "id": "12208", "attributes": { "award_id": "1R21AI179550-01", "title": "Feasibility of conducting HIV surveillance in community wastewater", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 28081, "first_name": "Gerald B.", "last_name": "Sharp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-23", "end_date": "2025-07-31", "award_amount": 231713, "principal_investigator": { "id": 28082, "first_name": "Julie", "last_name": "Parsonnet", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "At the start of the COVID-19 pandemic in late 2019, an estimated 1.2 million people—including 158,500 (13%) with undiagnosed infection—were living with HIV in the United States. Since then, HIV control efforts have been complicated by disruptions to HIV testing, care-related services, and case surveillance activities in state and local jurisdictions. However, the full impact of the COVID-19 pandemic on HIV transmission, incidence and outcomes has been difficult to quantify. Wastewater-based epidemiology (WBE) is a non-invasive and unbiased surveillance approach that can be used to estimate infectious disease occurrence in the population by detecting pathogen DNA or RNA in pooled community samples of wastewater. Here we propose to apply a novel WBE HIV surveillance method to measure HIV-1 nucleic acids in wastewater to estimate HIV incidence in sewersheds during the COVID-19 pandemic. This research study will pursue three specific aims: (1) to develop and validate a quantification method for HIV-1 nucleic acids (RNA and DNA) in urine, feces and wastewater settled solids, (2) in 30 people living with HIV, to c orrelate HIV nucleic acid (RNA and DNA) shedding in urine and feces with plasma viral load, and (3) using archived samples of wastewater rom Santa Clara and San Francisco Counties during the COVID pandemic, to determine trends in wastewater HIV-1 nucleic acid levels and compare findings with community case rates of HIV. The overarching goal of this project is to establish an HIV quantification method for wastewater-based surveillance using digital droplet, reverse transcription-PCR analysis that can be used to monitor HIV in the community. We hypothesize that wastewater surveillance can identify populations disproportionately affected by HIV, facilitating allocation of resources to those at highest risk, thereby maximizing HIV control. Investigating rates of changes in HIV nucleic acid in wastewater in relation to COVID-19 may also improve our understanding of how pandemic disease and its control strategies can impact HIV surveillance and patient care. Knowledge gained from this project will help establish a framework for wastewater-based surveillance for HIV in the US and globally that can reduce health disparities, improve health outcomes and prevent HIV transmission.", "keywords": [ "2019-nCoV", "AIDS prevention", "Affect", "Authorization documentation", "Biological Assay", "COVID-19", "COVID-19 pandemic", "COVID-19 pandemic effects", "California", "Caring", "Clinical", "Communicable Diseases", "Communities", "Complement", "County", "DNA", "Disease", "Disease Surveillance", "Ensure", "Feces", "Goals", "HIV", "HIV Infections", "HIV Seropositivity", "HIV diagnosis", "HIV-1", "HIV/AIDS", "Health", "Hospitalization", "Human", "Human immunodeficiency virus test", "Incidence", "Individual", "Infection", "Knowledge", "Measurement", "Measures", "Medical", "Methods", "Modeling", "Monitor", "Monkeypox", "National Institute of Allergy and Infectious Disease", "Nucleic Acids", "Outcome", "Pathogen detection", "Patient Care", "Persons", "Plasma", "Poliomyelitis", "Population", "Prevalence", "Public Health", "RNA", "Reduce health disparities", "Reporting", "Resource Allocation", "Reverse Transcriptase Polymerase Chain Reaction", "Reverse Transcription", "Risk Assessment", "Sampling", "San Francisco", "Services", "Sewage", "Solid", "Specimen", "Surveillance Methods", "System", "Testing", "Time", "Uncertainty", "United States", "Urine", "Viral", "Viral Load result", "Viremia", "Virus", "Visit", "Work", "authority", "community transmission", "cost effective", "digital", "feasibility testing", "high risk", "improved", "in vitro Assay", "infection risk", "interest", "novel", "pandemic disease", "pathogen", "prevent", "prevention service", "rate of change", "recruit", "research study", "response", "sample archive", "screening", "screening services", "stool sample", "success", "time use", "tool", "transmission process", "treatment services", "trend", "wastewater epidemiology", "wastewater samples", "wastewater surveillance", "wasting" ], "approved": true } }, { "type": "Grant", "id": "12209", "attributes": { "award_id": "1R21HD109408-01A1", "title": "Adapting COVID-19 Prenatal Care Innovations for Patients At Risk of Adverse Pregnancy Outcomes: a Mixed Methods Study of the Plan for Appropriate Tailored Healthcare in Pregnancy", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 8086, "first_name": "Maurice", "last_name": "Davis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-14", "end_date": "2025-07-31", "award_amount": 264736, "principal_investigator": { "id": 28083, "first_name": "Alex", "last_name": "Peahl", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "BACKGROUND: Prenatal care is a critical lever for improving maternity outcomes for the 4 million women who give birth annually. Yet, the traditional model of care—a uniform 14 in-person visits—overtreats and unduly burdens many patients. The COVID-19 pandemic rapidly transformed prenatal care delivery, prompting adoption of hybrid prenatal care models (reduced visit schedules with telemedicine). These changes are the basis for new national prenatal care consensus recommendations: the Plan for Appropriate Tailored Healthcare in pregnancy (PATH). Reduced visit schedules and telemedicine are supported by evidence and expert opinion, but it is unclear how hybrid prenatal care models will affect care utilization, health outcomes, and patient and provider experience, particularly for marginalized patient groups with the worst baseline outcomes. While PATH is promising for removing access barriers, changes could have unintended consequences (e.g. more unscheduled or delayed care). Thus, there is a critical need to evaluate the effects of hybrid prenatal care models to inform adaptations for widespread implementation for medically average-risk and marginalized patient populations. OVERALL STRATEGY: This research aims to understand how hybrid prenatal care models affect service utilization and health outcomes for average-risk patients, especially those from marginalized groups (low- income, Black, and rural patients). To achieve these goals, we will conduct econometric analyses to compare prenatal care utilization and outcomes from two institutions that have initiated and maintained hybrid prenatal care models to the present (Michigan Medicine, University of Pittsburgh Medical Center) with a control site (Indiana University) that adopted the hybrid prenatal care model only from March-May 2020 before returning to traditional care. We will used mixed methods to integrate EHR data with in-depth qualitative interviews to explain differences in utilization and critical adaptations needed to improve prenatal care delivery for average- risk and key marginalized groups. RESEARCH AIMS: Our study’s aims are: 1) Evaluate the effects of hybrid prenatal care models on care utilization and health outcomes for average-risk patients. 2) Explore how patient and provider factors affect utilization of hybrid prenatal care models to inform critical adaptations for optimizing prenatal care. IMPACT: This timely investigation is highly likely to exert a sustained, powerful impact on prenatal care delivery, maternal and neonatal outcomes, and equity, with potential for particular benefit among marginalized pregnant patients.", "keywords": [ "Accident and Emergency department", "Admission activity", "Adopted", "Adoption", "Affect", "American College of Obstetricians and Gynecologists", "Birth", "Birth Rate", "Black race", "COVID-19", "COVID-19 pandemic", "Caring", "Cesarean section", "Clinical", "Consensus", "Data", "Disparity", "Electronic Health Record", "Emergency department visit", "Ensure", "Equity", "Evaluation", "Expert Opinion", "Gestational Diabetes", "Goals", "Guidelines", "Gynecologist", "Health", "Health Services Accessibility", "Hybrids", "Incidence", "Indiana", "Institution", "Interview", "Investigation", "Knowledge", "Low income", "Medical", "Medical Liabilities", "Medical center", "Medicine", "Methods", "Michigan", "Modeling", "Neonatal", "Neonatal Intensive Care Units", "Outcome", "Outpatients", "Patients", "Pattern", "Persons", "Population", "Postpartum Depression", "Postpartum Period", "Pre-Eclampsia", "Pregnancy", "Premature Birth", "Prenatal care", "Provider", "Recommendation", "Research", "Research Design", "Risk", "Risk Factors", "Sampling", "Schedule", "Services", "Site", "Small for Gestational Age Infant", "Strategic Planning", "Subgroup", "Telemedicine", "Telephone", "Time", "Transportation", "United States", "United States National Institutes of Health", "Universities", "Visit", "Woman", "Work", "adverse outcome", "adverse pregnancy outcome", "barrier to care", "black patient", "care delivery", "care outcomes", "design", "econometrics", "experience", "high risk", "improved", "innovation", "intervention effect", "marginalization", "marginalized population", "maternal outcome", "neonatal outcome", "overtreatment", "pandemic disease", "patient population", "pregnant", "prenatal", "provider factors", "rural patients", "service utilization", "tailored health care", "traditional care" ], "approved": true } }, { "type": "Grant", "id": "12210", "attributes": { "award_id": "1R13AI179143-01", "title": "23rd Annual Rocky Mountain Virology Association Conference", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22573, "first_name": "Barbara L.", "last_name": "Mulach", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-10", "end_date": "2024-07-31", "award_amount": 7500, "principal_investigator": { "id": 24399, "first_name": "Rushika", "last_name": "Perera", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 323, "ror": "https://ror.org/03k1gpj17", "name": "Colorado State University", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 323, "ror": "https://ror.org/03k1gpj17", "name": "Colorado State University", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Program Summary / Abstract The Rocky Mountain Virology Association (RMVA) will hold its 23rd annual meeting September 29th-October 1st, 2023. The meeting brings together regional and national investigators in virology and prion biology for a 3-day retreat-style conference with extensive interaction and collaboration. The original meeting was organized by investigators in Colorado and Wyoming interested in free and open exchange of scientific data and ideas in virology in a venue that promotes collaboration among students, post-docs and faculty. Specifically, our annual meeting at the CSU Mountain Campus encourages young scientists to present their research and receive feedback from established scientists. The goals are promotion of scientific interactions and training. A major benefit of participation has been the novel collaborations that arise between scientists in different disciplines. Topics discussed include medical virology (vaccines, epidemiology, viral zoonoses), arthropod-borne diseases (RNA viruses, RNA metabolism, viral vectors and vector biology), host defenses (viral immunology and pathogenesis), prion biology, cancer biology and systems biology. Special sessions on vaccine development, pandemic viruses, virus discovery and the global impact of viral diseases have been common features. The 2021 meeting had a retrospective on the COVID-19 pandemic with discussions on successful approaches and establishment of systems for future challenges. The next meeting will feature discussions on Immune mechanisms of arthropod vectors, enteric and respiratory viruses (coronaviruses, rotaviruses and caliciviruses), arboviruses (flaviviruses and alphaviruses), prion diseases, organoid models, bat biology and reservoir hosts, host-pathogen interactions, and virus latency, epigenetics and host response . The meeting offers excellent collaborative opportunities. Attendees include scientists from CSU, University of Colorado, University of Wyoming, University of Northern Colorado, the Centers for Disease Control (Fort Collins) and the Department of Agriculture Animal and Plant Health Inspection Service, regional biotech companies, and universities in Iowa, Idaho, Nebraska, Kansas, Montana, New Mexico and Utah. The RMVA was incorporated in 2010 as an educational charity (501(c)(3)). Our volunteer board of directors is charged with encouraging student and junior faculty involvement by minimizing costs as we encourage women and minorities to participate in all stages of program presentation and development. Our attendance is limited to a maximum of 125 individuals, and the growth of the meeting to capacity illustrates the desire of regional scientists to participate. Funds for this proposal are requested to provide minority grants and childcare, reduced registration fees for graduate students, post- doctoral fellows and early-stage investigators, and for travel and housing for seven invited speakers. Registration fees, charitable contributions, and sponsorships cover the base costs for the meeting. The RMVA has been a source of communication and collaboration in the Rocky Mountain region, with outreach across the nation, for twenty-two years. NIAID support has expanded meeting interest to national and international levels.", "keywords": [ "Accreditation", "Agriculture", "Alphavirus", "Animal Diseases", "Animals", "Arboviruses", "Arthropod Vectors", "Biology", "Biotechnology", "Breathing", "COVID-19 pandemic", "Calicivirus", "Cancer Biology", "Centers for Disease Control and Prevention (U.S.)", "Charge", "Charities", "Child Care", "Chiroptera", "Clinical", "Collaborations", "Colorado", "Communicable Diseases", "Communication", "Coronavirus", "Data", "Dedications", "Development", "Discipline", "Education", "Enteral", "Epidemiologist", "Epidemiology", "Epigenetic Process", "Faculty", "Feedback", "Fees", "Flavivirus", "Fostering", "Funding", "Future", "Goals", "Government", "Grant", "Growth", "Health", "Host Defense", "Housing", "Idaho", "Immune", "Immune response", "Immunologist", "Immunology", "Individual", "Industrialization", "Institution", "International", "Iowa", "Kansas", "Laboratories", "Medical", "Mentors", "Minority", "Modeling", "Molecular", "Montana", "National Institute of Allergy and Infectious Disease", "Nebraska", "Neurologist", "New Mexico", "Organoids", "Pathogenesis", "Pathologist", "Persons", "Plants", "Postdoctoral Fellow", "Prion Diseases", "Prions", "Productivity", "RNA Viruses", "RNA metabolism", "Request for Proposals", "Research", "Research Personnel", "Rotavirus", "Scientist", "Senior Scientist", "Services", "Source", "Specialist", "Students", "System", "Systems Biology", "Training", "Travel", "Underrepresented Minority", "Universities", "Utah", "Vaccines", "Viral", "Viral Vector", "Virus", "Virus Diseases", "Virus Latency", "Woman", "Wyoming", "Zoonoses", "arboviral disease", "base", "biological systems", "college", "cost", "design", "graduate student", "human disease", "interdisciplinary approach", "interest", "medical specialties", "meetings", "novel", "outreach", "pandemic virus", "pathogen", "programs", "respiratory virus", "skills", "supportive environment", "symposium", "vaccine development", "vector", "virology", "volunteer" ], "approved": true } }, { "type": "Grant", "id": "12211", "attributes": { "award_id": "1R01DA059321-01", "title": "Multimodal Fetal and Placental Imaging and Biomarkers of Clinical Outcomes in Opioid Use Disorder", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 12931, "first_name": "Janani", "last_name": "Prabhakar", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-15", "end_date": "2026-07-31", "award_amount": 3145305, "principal_investigator": { "id": 28084, "first_name": "Rupa", "last_name": "Radhakrishnan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1621, "ror": "", "name": "INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "Maternal Opioid Use Disorder (OUD) and Neonatal Opioid Withdrawal Syndrome (NOWS) have dramatically increased, with an American child born suffering from NOWS every 15 minutes. The exponentially increasing prenatal opioid exposure (POE) and ongoing opioid epidemic are further worsened by the COVID-19 pandemic. Mothers with OUD are at risk of adverse pregnancy outcomes, and infants with POE are at risk for NOWS and poor long-term neurobehavioral outcomes; there are currently no objective tools for early prediction or mitigation of these risks. Our previous studies have shown MR imaging alterations in brain structural and resting state functional network connectivity in infants with POE compared to non-opioid exposed healthy infants. Specifically, we showed that, in infants with POE, thalamo-frontal functional connectivity correlated with severity of NOWS and was modulated by maternal comorbidities. Infant brain structural and functional development is dependent on placenta-fetal health. We identified smaller cerebellar dimensions in fetuses with prenatal opioid exposure and showed alterations in placental size in pregnant women on OUD who had concomitant smoking or polysubstance use. We also showed that opioid related poor childhood clinical outcomes are related to opioid pharmacogenetic variations, and that placental epigenetics is correlated with neonatal opioid withdrawal syndrome in POE. Our pilot data show that toddlers treated for NOWS score poorly on the cognitive domain of the Bayley Scales of Infant Development-III. Based on our pilot work, we hypothesize that opioids affect longitudinal fetal brain development resulting in adverse long-term childhood neurobehavioral outcomes and that these fetal brain effects are moderated by placental dysfunction and maternal comorbidities. There is a critical and urgent unmet need for proactive identification of novel comprehensive multimodal markers of placental and fetal brain growth and function to predict adverse maternal and infant outcomes in maternal OUD. Our long-term goal is to improve safety and efficacy of OUD treatment during pregnancy, and significantly reduce the risks of NOWS, poor childhood neurodevelopment and maternal relapse. The Specific Aims are to 1) determine the effects of opioids on the developing fetal brain through longitudinal structural and functional fetal brain MRI, 2) assess the impact of opioids on placental morphology and function through placental imaging, epigenetics, proteomics and opioid pharmacogenetics, and 3) correlate impaired fetal brain development and placental function with NOWS and infant neurodevelopmental outcomes. The expected outcomes are to identify 1) critical longitudinal imaging markers of placental dysfunction and altered fetal brain development in maternal OUD; 2) novel opioid pharmacogenetic, epigenetic and proteomic biomarkers of placental dysfunction in OUD and NOWS, and 3) comprehensive and advanced placental-fetal imaging, and circulating proteomic and placental epigenetic biomarkers of severity of NOWS and poor infant neurodevelopmental outcome.", "keywords": [ "2 year old", "Address", "Affect", "American", "Asphyxia Neonatorum", "Biological Markers", "Blood", "Brain", "Brain region", "Buprenorphine", "CCL17 gene", "COVID-19 pandemic", "Child", "Childhood", "Clinical", "Cognitive", "DNA", "Data", "Development", "Dimensions", "Economic Burden", "Epigenetic Process", "Fetal Development", "Fetal health", "Fetus", "Functional Magnetic Resonance Imaging", "Functional disorder", "Genes", "Genetic", "Genetic Variation", "Genomics", "Goals", "Growth", "Health", "Image", "Impairment", "Infant", "Infant Development", "Interleukin-1 beta", "Interleukin-2", "Knowledge", "Length of Stay", "Link", "Magnetic Resonance Imaging", "Mental Depression", "Metabolic Pathway", "Metabolism", "Methadone", "Methylation", "MicroRNAs", "Mothers", "Multimodal Imaging", "Neonatal Abstinence Syndrome", "Opioid", "Outcome", "Pharmacogenetics", "Pilot Projects", "Placenta", "Pregnancy", "Pregnancy Proteins", "Pregnant Women", "Premature Birth", "Proteome", "Proteomics", "Psychological Factors", "Public Health", "Relapse", "Reporting", "Research", "Research Personnel", "Rest", "Risk", "Safety", "Second Pregnancy Trimester", "Severities", "Site", "Smoking", "Structure", "Third Pregnancy Trimester", "Tissues", "Toddler", "Variant", "Vascular Endothelial Growth Factor D", "Work", "adverse outcome", "adverse pregnancy outcome", "behavioral outcome", "blood oxygen level dependent", "brain magnetic resonance imaging", "circulating biomarkers", "comparison control", "epigenetic marker", "fetal", "fetal opioid exposure", "high risk", "imaging biomarker", "improved", "individualized prevention", "infant outcome", "innovation", "magnetic resonance imaging biomarker", "maternal comorbidity", "maternal opioid use", "maternal outcome", "maternal risk", "medication for opioid use disorder", "morphometry", "multidisciplinary", "multimodality", "neurobehavioral", "neurodevelopment", "neuroimaging", "non-opioid analgesic", "novel", "opioid epidemic", "opioid use disorder", "opioid use in pregnancy", "personalized predictions", "placental morphology", "polysubstance use", "public health relevance", "risk mitigation", "serial imaging", "socioeconomics", "substance use", "tissue biomarkers", "tool", "uptake" ], "approved": true } }, { "type": "Grant", "id": "12212", "attributes": { "award_id": "1I01BX006273-01", "title": "Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-08-01", "end_date": "2027-07-31", "award_amount": null, "principal_investigator": { "id": 27400, "first_name": "Jay R", "last_name": "Radke", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2075, "ror": "https://ror.org/00mz0c648", "name": "Boise VA Medical Center", "address": "", "city": "", "state": "ID", "zip": "", "country": "United States", "approved": true }, "abstract": "Over 25% of US Veterans have diabetes, and those Veterans are at an increased risk of hospitalization and increased morbidity/mortality following severe respiratory viral infections, such as, influenza (H1N1), SARS- CoV-2 (COVID) and adenovirus (Ad). Infection with these respiratory viruses causes acute lung injury (ALI) that can result in acute respiratory distress syndrome (ARDS), with a mortality rate of ~40%. There are few therapeutic options for ALI/ARDS. Virus induced ALI/ARDS is driven primarily by uncontrolled inflammatory responses. Alveolar macrophages both induce and resolve ALI/ARDS, based on their polarization/inflammatory state. The plasticity of macrophages to vary between pro-inflammatory (M1, pro-ALI/ARDS) and anti- inflammatory (M2, anti-ALI/ARDS) phenotypes is driven by their metabolic states. Diabetes is a metabolic disorder in which levels of blood glucose are high and glycolysis is the preferred cellular metabolic pathway. Macrophages from diabetic patients have a high rate of glycolysis and an increased M1 phenotype. In addition, macrophages from diabetic patients have a lower rate of plasticity to change from M1 to M2 because of this shift to glycolysis. One possibility is that this glycolytic shift contributes to severe outcomes from respiratory viral infections in diabetic patients. The Syrian hamster is naturally permissive for influenza, SARS-CoV-2 and Ad (in contrast to other rodents that require viral adaptation). In addition, the Syrian hamster can naturally become diabetic with a high fat/high sugar diet. Ad14p1 is an emergent strain of Ad14 that has caused outbreaks of severe respiratory illness and ALI/ARDS throughout the world. Hamster infection with Ad14p1 results in a patchy bronchopneumonia, as seen in other severe human viral respiratory infections. In contrast, the prototype strain of Ad14 induces little lung inflammation. Other studies have shown that cells dying from Ad14 infection induce an M2-like human macrophage response, while cells dying from Ad14p1 infection fail to change M1 alveolar macrophages to an M2 phenotype. This dying infected cell activity is regulated by the expression of the Ad gene, E1B 20K. Cells infected by Ad14 produced sufficient E1B 20K to repolarize M1 macrophages to M2, while Ad14p1 infection does not produce sufficient E1B 20K, and the infected cells fail to alter M1 macrophage polarization. Therefore, the hamster model of Ad14p1 ALI/ARDS provides an appropriate system to study how diabetes affects macrophage polarization and pathogenesis during severe viral respiratory infections. The long-term goal of this project is to understand how emergent viruses regulate macrophage polarization to develop novel therapeutic strategies to drive macrophage polarization to an ALI/ARDS resolving phenotype in both diabetic and non-diabetic Veterans. To achieve this goal, a multi-omics approach will be used to identify and phenotype macrophages in normal and diabetic hamsters infected with Ad14p1. Transcriptomics using single-cell RNA sequencing will use gene expression profiles at the resolution of individual cells to identify and phenotype macrophages and their polarization states. Infiltrating immune cells and other lung resident cells will also be identified. Proteomics will be used to identify cytokines and chemokines that drive Ad14p1 pathogenesis. Metabolomics will be used to understand the unique metabolic changes in the lungs during Ad14p1 infection in diabetes and how those changes affect macrophage polarization. Comparative virology studies with infection of normal and diabetic hamsters with a pandemic strain of H1N1 influenza will be used to determine whether similar mechanisms of pathogenesis are involved in ALI/ARDS pathogenesis induced by other severe respiratory viruses. Finally, we will test the role of miRNA expression during prototype Ad14 and Ad14p1 infection in regulating macrophage polarization and pathogenesis, with the goals of defining mechanisms of immunomodulation and identifying candidate miRNAs that might be used as therapeutic agents against viral ALI/ARDS.", "keywords": [ "2019-nCoV", "Acute Lung Injury", "Acute Respiratory Distress Syndrome", "Adenovirus Protein", "Adenoviruses", "Affect", "Alveolar Macrophages", "Animal Model", "Anti-Inflammatory Agents", "Blood Glucose", "Bronchopneumonia", "COVID-19", "COVID-19 severity", "Cells", "Cessation of life", "Clinical", "Communicable Diseases", "Comparative Study", "Data", "Development", "Diabetes Mellitus", "Diet", "Disease", "Disease Outbreaks", "Etiology", "Fatty acid glycerol esters", "Functional disorder", "Future", "Gene Expression", "General Population", "Genes", "Glycolysis", "Goals", "Hamsters", "Hospital Mortality", "Hospitalization", "Human", "Immune response", "Impairment", "In Vitro", "Incidence", "Individual", "Infection", "Infection prevention", "Inflammation", "Inflammatory", "Inflammatory Response", "Influenza", "Influenza A Virus H1N1 Subtype", "Innate Immune Response", "Lung", "Lung infections", "Mediating", "Mesocricetus auratus", "Metabolic", "Metabolic Diseases", "Metabolic Pathway", "MicroRNAs", "Modeling", "Molecular", "Morbidity - disease rate", "Non-Insulin-Dependent Diabetes Mellitus", "Outcome", "Pathogenesis", "Pathogenicity", "Patients", "Pattern", "Phenotype", "Play", "Pneumonia", "Production", "Proteomics", "Pulmonary Inflammation", "Reporting", "Repression", "Resistance", "Resolution", "Risk", "Rodent", "Role", "SARS coronavirus", "SARS-CoV-2 infection", "Seasons", "Signal Repression", "Signal Transduction Pathway", "Structure", "System", "Testing", "Therapeutic", "Therapeutic Agents", "Therapeutic Intervention", "Veterans", "Viral", "Viral Pathogenesis", "Viral Respiratory Tract Infection", "Virus", "Virus Diseases", "candidate identification", "cell growth regulation", "chemokine", "comparative", "coronavirus disease", "cytokine", "design", "diabetic", "diabetic patient", "effective therapy", "experimental study", "high risk", "immune cell infiltrate", "immunoregulation", "in vivo", "influenza virus strain", "innovation", "lung injury", "macrophage", "metabolomics", "mortality", "multiple omics", "new therapeutic target", "non-diabetic", "novel", "novel therapeutic intervention", "pandemic disease", "permissiveness", "prevent", "prototype", "pulmonary function", "respiratory", "respiratory virus", "response", "single-cell RNA sequencing", "sugar", "transcriptomics", "virology", "western diet" ], "approved": true } }, { "type": "Grant", "id": "12213", "attributes": { "award_id": "1UH2AI178082-01", "title": "Investigating the molecular mechanisms of membrane remodeling by coronaviruses", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 27781, "first_name": "Mary Katherine Bradford", "last_name": "Plimack", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-16", "end_date": "2025-07-31", "award_amount": 204427, "principal_investigator": { "id": 28085, "first_name": "Michael Joseph", "last_name": "Ragusa", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 386, "ror": "https://ror.org/049s0rh22", "name": "Dartmouth College", "address": "", "city": "", "state": "NH", "zip": "", "country": "United States", "approved": true }, "abstract": "Coronaviruses are enveloped positive-sense RNA viruses. Over the last two decades, coronaviruses have led to severe respiratory infections in humans. Most recently, SARS-CoV-2 led to a global pandemic and resulted in more than 6.5 million deaths globally since December 2019. We currently lack a sufficiently broad set of antiviral drugs targeting different aspects of coronavirus replication. Therefore, developing new antiviral drugs targeting currently untargeted aspects of coronavirus replication may help reduce the mortality of future coronavirus infections. As such, it is critical to understand the molecular mechanisms of many different aspects of coronavirus replication as this will help to determine which aspects of viral replication may be useful targets for the development of new antiviral drugs. One aspect of coronavirus replication that is not well understood is the mechanisms by which coronaviruses remodel host cell membranes. Once coronaviruses infect host cells, a set of nonstructural proteins (nsps) are produced from the viral RNA. Three of these nsps, nsp3, nsp4 and nsp6, are integral membrane proteins that remodel host cell membranes to generate double-membrane vesicles (DMVs) from the endoplasmic reticulum (ER). These DMVs serve as the assembly sites for the replication and transcription complexes that are critical to producing viral RNA. In addition, DMVs have been shown to contain viral RNA further highlighting the critical role of DMVs in viral RNA production. While it is clear that membrane remodeling by coronaviruses is essential for their replication, we currently lack an understanding of the molecular mechanisms by which coronaviruses remodel host cell membranes to generate DMVs. One major reason for our limited understanding of this process, is that no studies have investigated the structure and function of the membrane-spanning regions of nsp3, nsp4 and nsp6 using purified proteins. As such, we will purify nsp3, nsp4 and nsp6 for structural studies using cryo-EM and for biochemical investigations using model membranes including liposomes and giant unilamellar vesicles. Importantly, this will work will not only provide new insight into the mechanisms of coronavirus replication, but it will also help reveal if membrane remodeling by coronaviruses may be a useful target for the development of future antiviral drugs.", "keywords": [ "2019-nCoV", "Amino Acids", "Antiviral Agents", "Appearance", "Binding", "Biochemical", "Biological Assay", "Cell membrane", "Cells", "Cessation of life", "Complex", "Confocal Microscopy", "Coronavirus", "Coronavirus Infections", "Cryo-electron tomography", "Cryoelectron Microscopy", "Detergents", "Development", "Drug Targeting", "Endoplasmic Reticulum", "Fluorescence Spectroscopy", "Freezing", "Future", "Genetic Transcription", "Healthcare Systems", "Human", "In Vitro", "Infection", "Integral Membrane Protein", "Investigation", "Length", "Liposomes", "Membrane", "Membrane Structure and Function", "Middle East Respiratory Syndrome Coronavirus", "Molecular", "Nonstructural Protein", "Population", "Positioning Attribute", "Process", "Production", "Protein Region", "Proteins", "RNA Transport", "RNA Viruses", "Resolution", "Respiratory Tract Infections", "Role", "SARS coronavirus", "Shapes", "Shelter facility", "Site", "Social Distance", "Structure", "Surface", "Testing", "Transmembrane Domain", "Vaccines", "Vesicle", "Viral Nonstructural Proteins", "Virus", "Virus Replication", "Work", "experimental study", "fighting", "human pathogen", "insight", "membrane model", "membrane reconstitution", "mortality", "novel", "novel coronavirus", "pandemic disease", "particle", "protein purification", "protein structure", "reconstitution", "screening", "success", "tool", "transmission process", "unilamellar vesicle", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "12214", "attributes": { "award_id": "1UC7AI180314-01", "title": "Resources and Workforce Development for the Tulane Regional Biocontainment Laboratory", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 27982, "first_name": "FAYNA C", "last_name": "Diaz San Segundo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-22", "end_date": "2028-07-31", "award_amount": 2878190, "principal_investigator": { "id": 6569, "first_name": "JAY", "last_name": "RAPPAPORT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 811, "ror": "", "name": "TULANE UNIVERSITY OF LOUISIANA", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 811, "ror": "", "name": "TULANE UNIVERSITY OF LOUISIANA", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Tulane National Primate Research Center (TNPRC) is one of seven National Primate Research Centers (NPRCs) dedicated to conducting nonhuman primate (NHP) research with the goal of improving human health. With a primary focus on infectious disease and biodefense research, the TNPRC is only NPRC with a Regional Biocontainment Laboratory (RBL) at Biosafety Level 3 (BSL-3) for the study of high-consequence pathogens, including select agents and toxins. The Tulane University RBL, which came online in June 2010, has been critical for advancing research at the TNPRC and across the region on biodefense agents and emerging infectious diseases, with a primary focus on in vivo studies using NHPs. Since its inception, significant infrastructure projects have been completed to capitalize on the presence of the RBL and grow and diversify research at the TNPRC. In recent years, and particularly with the onset of the COVID-19 pandemic, the TNPRC RBL has expanded its capabilities and capacity to accommodate BSL-3-level emerging pathogen and biodefense research. The overarching goal of the proposed project is to strategically enhance and fortify BSL-3 research capabilities within the TNPRC RBL to ensure the long-term success of this program in support of infectious disease and biodefense research and countermeasure development. This will be accomplished through the following Specific Aims: (1) Ensure agility of the TNPRC RBL response to emerging public health concerns and threats by leveraging the robust research infrastructure and unique research strengths of the TNPRC and implementing exceptional preventative maintenance processes that allow for best practices, quality control, and extensive safety oversight for work with high- consequence pathogens. (2) Provide formal structure for sharing of best practices for safety, research procedures and facilities management with partners and other RBLs. (3) Coordinate practices and procedures across the Biodefense Facilities Network to leverage the strengths of all 12 RBLs; ensure efficient and effective cross-training and sharing of methodologies, SOPs, and best practices; and coordinate and advance infectious disease and biodefense research and countermeasure development nation-wide.", "keywords": [ "COVID-19", "COVID-19 pandemic", "Communicable Diseases", "Dedications", "Development", "Emerging Communicable Diseases", "Ensure", "Equipment", "Funding", "Goals", "Grant", "Health", "Human", "Infrastructure", "Laboratories", "Maintenance", "Methodology", "National Institute of Allergy and Infectious Disease", "Operative Surgical Procedures", "Primates", "Procedures", "Process", "Public Health", "Quality Control", "Research", "Research Infrastructure", "Resource Development", "Safety", "Structure", "Toxin", "Training", "United States National Institutes of Health", "Universities", "Work", "Workforce Development", "animal colony", "base", "biodefense", "biosafety level 3 facility", "emerging pathogen", "fortification", "germ free condition", "improved", "in vivo", "medical countermeasure", "nonhuman primate", "operation", "pandemic preparedness", "pandemic response", "pathogen", "programs", "response", "safety practice", "success" ], "approved": true } }, { "type": "Grant", "id": "12215", "attributes": { "award_id": "1R15EB034552-01", "title": "High-throughput high-resolution microscopy for phenotypic drug discovery applications", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 23661, "first_name": "AFROUZ AZARI", "last_name": "Anderson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-01", "end_date": "2026-07-31", "award_amount": 451500, "principal_investigator": { "id": 28086, "first_name": "Aniruddha", "last_name": "Ray", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 451, "ror": "https://ror.org/01pbdzh19", "name": "University of Toledo", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "Abstract: Multidrug resistance (MDR) is a major cause of chemotherapy failure in cancer and a major public health concern. Often, MDR cancers are aggressive, metastatic, and have poor prognoses. In addition, MDR cancer is highly resistant to treatments that induce conventional programmed cell death, such as chemotherapy and radiation. For the purpose of combating apoptosis mediated MDR, new drug discoveries are being directed towards therapies that induce apoptosis-inhibiting processes, such as necroptosis, autophagy, paraptosis, methuosis, and ferroptosis. When optimizing new chemical molecules during the early phases of drug discovery, two key questions need to be addressed: a) the ability of the drug to kill cancer cells, and b) the mechanism by which the drug kills cancer cells. At present, conventional biochemical assays and high-definition imaging are the only methods for studying these processes, but they are time consuming, costly, and require skilled experts, thus limiting their utility to a small number of laboratories. We propose a paradigm-altering phenotypic screening tool that identifies cell death mechanisms in real time using high-resolution widefield microscopy coupled with deep learning. First, we propose to develop a low-cost widefield holographic microscope, with multi-wavelength illumination, including ultraviolet (UV), to enable high content screening without external labeling, at high resolution that exceeds the diffraction limit. We will achieve this by integrating lens-less holographic microscopy with microparticle array-based imaging substrates that will allow us to image thousands of live cells per test. UV illumination may provide extra information about nuclei and other organelles of cells, even though it is used sparingly. Using time lapse images of cancer cells, a 3D- convolutional neural network will be trained to identify different morphological features, such as shrinking, blebbing, vacuoles and membrane ruptures, associated with different cell death processes. During the incubation step, results will be obtained in real time, using the pre-trained network for automated classification of the cell death process. Using this approach, new anti-cancer drug molecules and their intermediates can be screened at high-throughput without requiring any further processing or labeling. A successful completion of this project will result in an affordable, compact, high-content screening tool that can be used for many different applications, in addition to phenotypic screening. In particular, during this Covid-19 crisis, which has highlighted the need for high throughput diagnostics, drug screening, and therapy tools. By implementing this AREA award, we will significantly strengthen University of Toledo's research climate and provide undergraduate students with a unique interdisciplinary training experience in biophysics, microscopy, imaging, deep learning, cell biology, and pharmacology.", "keywords": [ "3-Dimensional", "Address", "Antineoplastic Agents", "Antitumor Drug Screening Assays", "Apoptosis", "Apoptotic", "Artificial Intelligence", "Autophagocytosis", "Award", "Biochemical", "Biological Assay", "Biophysics", "Buffers", "Bulla", "Bypass", "COVID-19 pandemic", "Cancer Model", "Cell Death", "Cell Death Induction", "Cell Death Process", "Cell Nucleus", "Cell model", "Cells", "Cellular Morphology", "Cellular biology", "Cessation of life", "Characteristics", "Chemicals", "Chemotherapy and/or radiation", "Classification", "Climate", "Clinic", "Clinical Trials", "Consumption", "Coupled", "Development", "Devices", "Diagnostic", "Doxorubicin", "Drug Screening", "First Generation College Students", "Goals", "Holography", "Hydrogen Peroxide", "Image", "Incubated", "Induction of Apoptosis", "Inhibition of Apoptosis", "Institution", "Label", "Laboratories", "Lighting", "Malignant Neoplasms", "Measurement", "Mediating", "Membrane", "Methods", "Microscope", "Microscopy", "Mitotic", "Modeling", "Molecular", "Morphology", "Multi-Drug Resistance", "Necrosis", "Neoplasm Metastasis", "Organelles", "Pathway interactions", "Patients", "Pharmaceutical Preparations", "Pharmacology", "Phase", "Phenotype", "Physiological", "Process", "Prognosis", "Property", "Public Health", "Research", "Research Personnel", "Resistance", "Resistance development", "Resolution", "Rupture", "Screening procedure", "Series", "Speed", "Technology", "Testing", "Time", "Toxic effect", "Training", "Treatment Failure", "Underrepresented Minority", "Universities", "Vacuole", "Visualization", "anti-cancer", "anticancer research", "cancer cell", "cancer drug resistance", "cancer imaging", "cell type", "chemotherapy", "college", "convolutional neural network", "cost", "cost effective", "cytotoxicity", "deep learning", "disadvantaged background", "drug discovery", "economic disparity", "experience", "experimental study", "high resolution imaging", "high throughput screening", "imaging system", "improved", "minority communities", "mortality", "novel", "novel anticancer drug", "novel strategies", "novel therapeutics", "particle", "phenotypic data", "response", "screening", "simulation", "skills", "therapeutic candidate", "time use", "tool", "two-dimensional", "ultraviolet", "undergraduate student" ], "approved": true } }, { "type": "Grant", "id": "12216", "attributes": { "award_id": "1UM1TR004548-01", "title": "The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve Health", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21790, "first_name": "Pablo", "last_name": "Cure", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-22", "end_date": "2030-07-31", "award_amount": 5622982, "principal_investigator": { "id": 28087, "first_name": "CYNTHIA A", "last_name": "GERHARDT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28088, "first_name": "Matthew D", "last_name": "Ringel", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 778, "ror": "", "name": "OHIO STATE UNIVERSITY", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "ABTRACT The Ohio State University (OSU) Center for Clinical and Translational Science (CCTS) was formed in 2007, with the vision to advance today’s discoveries to improve health for all. We employed a comprehensive approach to address the full spectrum of T1-T4 science via the education and career development of a highly trained workforce integrated with a robust system of CTR resources. We provided leadership in the CTSA Consortium through sharing of tools and methods to advance CTR; adopted innovations from other hubs; and fully engaged in CTSA Consortium activities (e.g., multisite trials). We also supported community engaged research addressing the most pressing health issues in our communities (e.g., opioid crisis, COVID-19). Yet, work remains. Thus, we build upon unique strengths at OSU/NCH and in Ohio’s communities. We have leveraged our strategic investment in data sciences, a robust environment of resources, and a vibrant CTR community to address CTS gaps and barriers. We will now address five CTS roadblocks to improve the quality, efficiency, and rigor of CTR: (1) need for improved efficiencies and effectiveness to advance CTR and ensure results are disseminated and implemented into healthcare; 2) education and training innovations do not reach the full CTR workforce, resulting in a declining and inadequately diverse CTS workforce, lacking the knowledge and skills to advance CTR; 3) limited authentic participation by diverse stakeholders across the research life cycle; 4) growth of complex datasets necessitates integration of clinical, environmental, and research data, with need for democratization of data accessibility to advance data equity; and 5) racial injustice, SDoH, the CTR teams we form, and interpretation of our results impact health disparities. Applying a health equity and DEIA framework to every activity, we will pursue five aims: Aim 1: Develop innovations in methods, approaches, and tools to address pressing roadblocks facing CTR. Aim 2: Support training and career development of the full CTS workforce. Aim 3: Engage voices from across academic and scientific disciplines, patients, communities, and industry to conduct CTR and CTS across the full lifecycle of the scientific process. Aim 4: Deploy an accessible, responsive, and integrated system of research resources. Aim 5: Democratize informatics resources by lowering the cost of entry for data access and computing resources. With a commitment to metric-driven decision-making, we will evaluate the impact of the CCTS by applying the RE- AIM framework to inform strategic pivots over the next 7 years. This proposal reaffirms our commitment to advance CTS and expands our engagement with stakeholders to increase rigorous, impactful, and relevant CTR. We will develop, share, and adopt innovations through focused CTS to enhance CTR for the communities we serve and those we engage. These resources, skilled workforce, and institutional strengths provide an agile foundation to facilitate rapid responses to emerging public health issues, and will ensure an equity lens is applied to all CTR so no one is left behind from the advances of CTR to improve human health.", "keywords": [ "Address", "Adopted", "Appalachian Region", "Applied Research", "COVID-19", "Clinical", "Clinical Research", "Clinical Sciences", "Clinical and Translational Science Awards", "Collaborations", "Communities", "Data", "Data Science", "Data Set", "Decision Making", "Democracy", "Development", "Discipline", "Disparity", "Dissemination and Implementation", "Education", "Effectiveness", "Ensure", "Environment", "Equity", "Faculty", "Foundations", "Funding", "Grant", "Growth", "Health", "Healthcare", "Human", "Individual", "Industry", "Infant", "Infrastructure", "Institution", "Investments", "Knowledge", "Leadership", "Left", "Life Cycle Stages", "Maternal Mortality", "Medical center", "Methods", "Ohio", "Outcomes Research", "Patients", "Pediatric Hospitals", "Population", "Process", "Public Health", "Racial injustice", "Reach Effectiveness Adoption Implementation and Maintenance", "Research", "Research Design", "Research Personnel", "Resource Informatics", "Resources", "Rural", "Science", "System", "Systems Integration", "Thinking", "Training", "Training Support", "Training and Education", "Translational Research", "Universities", "Validation", "Vision", "Voice", "Work", "career development", "clinical center", "clinical translation", "clinically relevant", "college", "community engaged research", "complex data", "computing resources", "cost", "data access", "demographics", "health care delivery", "health disparity", "health equity", "implementation science", "improved", "innovation", "lens", "member", "multi-site trial", "novel strategies", "opioid epidemic", "response", "skills", "social", "social health determinants", "tool", "translational pipeline" ], "approved": true } }, { "type": "Grant", "id": "12217", "attributes": { "award_id": "1R33AT012022-01A1", "title": "Beetroot Juice Supplement for Boosting Mucosal Immunity – The NO Cold Study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Complementary and Integrative Health (NCCIH)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 8626, "first_name": "Wendy J.", "last_name": "Weber", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-23", "end_date": "2026-05-31", "award_amount": 518775, "principal_investigator": { "id": 28089, "first_name": "Thomas Ekkehard", "last_name": "Ritz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 370, "ror": "https://ror.org/042tdr378", "name": "Southern Methodist University", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Respiratory tract infections cause a considerable burden to health care systems and societies as a whole, which has been exasperated by COVID-19. Available preventative treatments for respiratory infections and the common cold have remained unsatisfactory and are often not adhered to. Psychological factors, such as stress, increase risk for respiratory infections and the common cold. A possible mechanism for this relationship could be reduced levels of nitric oxide (NO), which serve as a first-line defense mechanism. NO is reduced during periods of psychological stress, such as academic finals in students. Boosting levels of NO during periods of stress may provide a prevention strategy for respiratory infections, especially in populations with high transmission risk. Our pilot data suggests that beetroot juice elevates the fraction of exhaled NO (FENO) and attenuates cold symptoms during stressful final exams. The current study proposes a three-arm, double-blinded, and placebo-controlled trial design (conditions: one daily active dose and one daily placebo dose, two daily active doses, two daily placebo doses, with 50 participants in each condition, total N=150), with students under final examination stress, to examine the usefulness of beetroot juice in elevating airway NO measured by FENO and thereby reducing respiratory viral infections tested by viral polymerase chain reaction. The current study will 1) demonstrate that a 7-day trial of daily beetroot juice or de-nitrated placebo beetroot juice is feasible logistically and with acceptable adherence during a period of real-life stress, 2) generate initial evidence for the capacity of beetroot juice to increase elevations in FENO, which correlates with reductions in infection using respiratory viral panel, (biological signature), 3) examine dosage effects, in that two daily active doses of beetroot juice are likely more potent than one daily dose or placebo in elevating FENO. The trial will use a well-controlled paradigm of a naturalistic stress to demonstrate that airway NO production is the critical target mechanism underlying the beneficial effects of dietary nitrate supplementation on respiratory tract infection and common cold symptoms. Two university sites will recruit participants and their findings and experience in team integration will prepare a regular-size two-arm, double-blind randomized controlled clinical trial of beetroot juice effects on respiratory infection, which will include additional recruitment sites across the Southwestern US.", "keywords": [ "Absenteeism at work", "Adherence", "Adverse effects", "Attenuated", "Biological", "Buffers", "COVID-19", "Cardiovascular system", "Cellular Phone", "Cessation of life", "Chronic stress", "Clinical Trials", "Common Cold", "Cytostatics", "Data", "Defense Mechanisms", "Dependence", "Developed Countries", "Development", "Dietary Intervention", "Dose", "Double-Blind Method", "Economic Burden", "Epithelial Cells", "Exercise Physiology", "Exhalation", "Feasibility Studies", "Healthcare Systems", "Hour", "Human", "Hydrocortisone", "Infection", "Intake", "Intervention", "Juice", "Life Stress", "Link", "Lung", "Measures", "Mediation", "Medicine", "Mental Depression", "Monitor", "Mucosal Immunity", "N N-dimethylarginine", "Nitrates", "Nitric Oxide", "Nitric Oxide Pathway", "Nitrites", "Outcome", "Outcome Assessment", "Participant", "Patient Recruitments", "Placebo Control", "Placebos", "Polymerase Chain Reaction", "Population", "Predisposition", "Prevention", "Prevention approach", "Prevention strategy", "Preventive treatment", "Procedures", "Production", "Productivity", "Property", "Protein Secretion", "Protocols documentation", "Psychological Factors", "Psychological Stress", "Psychosocial Factor", "Psychosocial Stress", "Randomized Controlled Clinical Trials", "Reporting", "Research", "Respiratory Mucosa", "Respiratory Tract Infections", "Rhinovirus infection", "Risk", "Sampling", "Severities", "Signal Transduction", "Site", "Social support", "Societies", "Source", "Stress", "Students", "Supplementation", "Symptoms", "Testing", "Tissues", "Universities", "Video Recording", "Viral", "Viral Respiratory Tract Infection", "Virus Diseases", "Visit", "arginase", "arm", "cost", "cytotoxic", "dietary nitrate", "dosage", "double-blind placebo controlled trial", "evidence base", "experience", "follow up assessment", "infection risk", "inhibitor", "insight", "novel", "novel strategies", "pathogen", "placebo controlled trial", "prophylactic", "public health relevance", "randomized clinical trials", "recruit", "reduce symptoms", "respiratory", "sex", "transmission process", "trial design", "young adult" ], "approved": true } } ], "meta": { "pagination": { "page": 1391, "pages": 1424, "count": 14236 } } }